Sign in
Taking people in FrancePhase 1

Tests etanercept with repeated ultrasound in people with Alzheimer's disease

Checks the safety of etanercept given with repeated ultrasound scans in adults with Alzheimer's.

Key facts

Who runs it
Hopital Fondation Adolphe De Rothschild
Where
Paris, FranceSee the site
Registry title
Evaluation of the safety of a strategy combining etanercept administration with repeated contrast ultrasound in patients with Alzheimer's disease: a phase I study
Status
Recruiting
Phase
Phase 1
People taking part
5 people, planned
Started
16 Apr 2025
Expected to end
2 Oct 2027
Type of study
Interventional
Record updated
21 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Alzheimer's disease to test the safety of etanercept given together with repeated contrast ultrasound.

Age
18 years and older
Sex
All sexes can join.

This trial is currently available in France.

  • Hopital Fondation Adolphe de RothschildParis, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests etanercept with repeated ultrasound in people with Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 May 2026